Mineralys sees stock surge on lorundrostat data

11 March 2025

Mineralys Therapeutics (Nasdaq: MLYS) has reported positive top-line results from two pivotal trials evaluating lorundrostat, a potentially new option for uncontrolled and resistant hypertension.

The company said both studies, Launch-HTN and Advance-HTN, met their primary endpoints with statistically-significant reductions in blood pressure.

The Phase III Launch-HTN study demonstrated a 9.1 mmHg placebo-adjusted reduction in systolic blood pressure at six weeks, while the Advance-HTN trial saw a 7.9 mmHg reduction at 12 weeks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology